Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells

Xenobiotica

Volumn 39, Issue 3, 2009, Pages 205-217

  Choi, S ^a   Sainz Jr , B ^a   Corcoran, P ^a   Uprichard, S ^a   Jeong, H ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

Differentiation; Dimethyl sulfoxide (DMSO); Drug metabolism; Huh7 cells

Indexed keywords

3 METHYLCHOLANTHRENE; ALBUMIN; AROMATIC HYDROCARBON RECEPTOR; BUFURALOL; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXTROMETHORPHAN; DICLOFENAC; DIMETHYL SULFOXIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; LAMOTRIGINE; MEPHENYTOIN; MESSENGER RNA; MIDAZOLAM; MORPHINE; PREALBUMIN; PREGNANE X RECEPTOR; RETINOID X RECEPTOR ALPHA; PRIMER DNA;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; HEPATOMA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; DRUG EFFECT; GENE EXPRESSION REGULATION; LIVER CELL; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1A1; DIMETHYL SULFOXIDE; DNA PRIMERS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATOCYTES; HUMANS; METHYLCHOLANTHRENE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 66149122259     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802613620     Document Type: Article

References (46)

1. Alexandre E, Davida P, Viollonb C, Wolfa P, Jaecka D, Azimzadeha A, Nicodb L, Boudjemaa K, Richertb L. 1999. Expression of cytochromes P-450 2E1, 3A4 and 1A1/1A2 in growing and confluent human HepG2 hepatoma cells - effect of ethanol. Toxicol In Vitro 13:427-435.
2. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, Guguen-Guillouzo C, Guillouzo A. 2006. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75-83.
3. Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. 2003. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem 278:32852-32860.
4. Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS, Coleman RA, Brown AM. 2000. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 28:781-788.
5. Castell JV, Gomez-Lechon MJ, Ponsoda X, Bort R. 1997. The use of cultured hepatocytes to investigate the mechanisms of drug hepatotoxicity. Cell Biol Toxicol 13:331-338.
6. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
7. Csala M, Staines AG, Banhegyi G, Mandl J, Coughtrie MW, Burchell B. 2004. Evidence for multiple glucuronide transporters in rat liver microsomes. Biochem Pharmacol 68:1353-1362.
8. Deeley RG, Westlake C, Cole SP. 2006. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849-899.
9. Donato MT, Castell JV, Gomez-Lechon MJ. 1995. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab Dispos 23:553-558.
10. Duverlie G, Wychowski C. 2007. Cell culture systems for the hepatitis C virus. World J Gastroenterol 13:2442-2445.
11. Gardner-Stephen D, Heydel JM, Goyal A, Lu Y, Xie W, Lindblom T, Mackenzie P, Radominska-Pandya A. 2004. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab Dispos 32:340-347.
12. Goldring CE, Kitteringham NR, Jenkins R, Lovatt CA, Randle LE, Abdullah A, Owen A, Liu X, Butler PJ, Williams DP et al. 2006. Development of a transactivator in hepatoma cells that allows expression of Phase I, Phase II, and chemical defense genes. Am J Physiol Cell Physiol 290:C104-C115.
13. Gomez-Lechon MJ, Castell JV, Donato MT. 2007. Hepatocytes - the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem Biol Interact 168:30-50.
14. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. 2004. Human hepatocytes in primary culture: The choice to investigate drug metabolism in man. Curr Drug Metab 5:443-462.
15. Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G, Bukh J. 2007. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133:1614-1626.
16. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. 2007. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 168:66-73.
17. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. 2003. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 88:1323-1332.
18. Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, Houston JB. 2006. Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res 23:533-539.
19. Hallifax D, Rawden HC, Hakooz N, Houston JB. 2005. Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab Dispos 33:1852-1858.
20. Hewes JC, Riddy D, Morris RW, Woodrooffe AJ, Davidson BR, Fuller B. 2006. A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: The effects of prior exposure to chemotherapy. J Hepatol 45:263-270.
21. Hewitt NJ, Hewitt P. 2004. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 34:243-256.
22. Huang H, Chen Y, Ye J. 2007. Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci USA 104:18666-18670.
23. Kanebratt KP, Andersson TB. 2008. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444-1452.
24. Kogure T, Ueno Y, Iwasaki T, Shimosegawa T. 2004. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol 53:296-304.
25. Ledirac N, de Sousa G, Fontaine F, Agouridas C, Gugenheim J, Lorenzon G, Rahmani R. 2000. Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin. Drug Metab Dispos 28:1391-1393.
26. Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL, Cheng LK. 1997. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 107:17-30.
27. Ma Q, Lu AY. 2007. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 35:1009-1016.
28. Mankowski DC. 1999. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6. Drug Metab Dispos 27:1024-1028.
29. Martignoni M, Groothuis GM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
30. Morgan ET. 2001. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 29:207-212.
31. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. 1982. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42:3858-3863.
32. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ. 2007. Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol 222:42-56.
33. Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, Maurel P. 2008. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 48:1-32.
34. Phillips A, Hood SR, Gibson GG, Plant NJ. 2005. Impact of transcription factor profile and chromatin conformation on human hepatocyte CYP3A gene expression. Drug Metab Dispos 33:233-242.
35. Radominska-Pandya A, Bratton S, Little JM. 2005. A historical overview of the heterologous expression of mammalian UDPglucuronosyltransferase isoforms over the past twenty years. Curr Drug Metab 6:141-160.
36. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. 2006. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062.
37. Sainz B, Jr, Chisari FV. 2006. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma- derived cells. J Virol 80:10253-10257.
38. Takagi S, Nakajima M, Mohri T, Yokoi T. 2008. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283:9674-9680.
39. Tassaneeyakul W, Birkett DJ, McManus ME, Veronese ME, Andersson T, Tukey RH, Miners JO. 1994. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 47:1767-1776.
40. Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. 2007. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 37:1225-1256. (Pubitemid 350035532)
41. Von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI. 1998. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 50:997-1004.
42. Wadelius M, Darj E, Frenne G, Rane A. 1997. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 62:400-407.
43. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT. 2003. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433-440.
44. Yu A, Haining RL. 2001. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-1520.
45. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. 2002. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319.
46. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102:9294-9299.